EC Microbiology

Extended spectrum beta lactamases (ESBL) producing Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae)
emerged as a major problem in nosocomial infection all over the world due to their resistance to the extended spectrum Cephalo-
sporin.

Thus the aim of this study was to determine the high prevalence of ESBL producing E. coli and K. pneumoniae among hospitalized
patients to put a proper antimicrobial therapy guideline to treat infections caused by these organisms at small hospital.
A total of 92 clinical isolates were isolated where ESBL-producing E. coli and K. pneumoniae were confirmed by automated system
VITEK 2 (Biomerieux) and susceptibility test using common antibiotics.

Among 92 clinical isolates 56 (60.86%) were E. coli and K. pneumoniae. All the clinical isolates were from the inpatients units
obtained from different clinical specimens of Wadi Aldawasir hospital from April to August 2016.The overall prevalence of ESBL-
producing E. coli and K. pneumoniae was 84% (47/56).The prevalence of ESBL-producing E. coli was found to be high 68%(32/47).
Antibiogram pattern of these isolates confirmed, Tigecycline to be the drug of choice for ESBL producing E. coli and Amikacin for
ESBL producing K. pneumoniae. Advance drug resistance surveillance is necessary to guide appropriate use of antibiotics.

Keywords: Extended Spectrum Beta Lactamases (ESBL); Escherichia coli; Klebsiella pneumonia; Antibiogram; Antimicrobial Susceptibility

1. Pitout JD and Lapland KB. “Extended spectrum-beta-lactamase-producing Enterobacteriaceae: an emerging public health concern”. The Lancet Infectious Diseases 8.3 (2008): 156-166.
2. Paterson DL and Bonomo RA. “Extended-spectrum beta-lactamase: a clinical update”. Clinical Microbiology Reviews 18.4 (2005): 657-686.
3. Kenneth S Thomson. “Extended-Spectrum-beta-lactamase, AmpC, and Carbapenemase”. Journal of Clinical Microbiology 48.4 (2010): 1019-1102.
4. Adriane Lenhard., et al. “High prevalence rate of ESBL among Enterobacteriaceae in small Brazilian public hospital”. Brazilian Journal of Pharmaceutical Sciences 47.4 (2011).
5. Etok CA., et al. “Etiology and antimicrobial studies of surgical wound infections in university of Uyo teaching hospital(UUTH), Uyo, Akwa Ibom state, Nigeria”. Open Access Scientific Reports 1 (2012): 341.
6. Saraswathi R., et al. “Occurrence of Extended Spectrum Beta Lactamase (ESBL) Producers in Postoperative Wound Infection”. Scholars Journal of Applied Medical Sciences 3.2G (2015): 995-999.
7. Hawkey PM. “The growing burden of antimicrobial resistance”. Journal of Antimicrobial Chemotherapy 62.1 (2008): i1-i19.
8. Deepti Rawat and Deepthi Nair. “Extended-spectrum ß-lactamases in gram-negative bacteria”. Journal of Global Infectious Diseases 2.3 (2010): 263-274.
9. CHW P & P Guideline. “Extended Spectrum Beta-Lactamase (ESBL) producing Gram Negative Bacilli: Infection Control Management” (2016).
10. Provincial Infection Control (PIC-NL), Fact Sheet for Healthcare Professionals Dec 2011 Vitro susceptibilities of aerobic and faculta- tive anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide:.
11. Baquero F., et al. “Extended-Spectrum Beta-Lactamases (ESBL) producing bacteria”. Surgical Infections (2009).
12. Hadi Mehrgan., et al. “High prevalence of extended-spectrum beta –lactamase-producing Klebsiella pneumoniae in tertiary care hos- pital in Tehran, Iran”. Journal of Infection in Developing Countries 4.3 (2010): 132-138.
13. Reinert RR., et al. “Antimicrobial susceptibility among organisms from the Asia/ Pacific Rim, Europe and Latin and North America collected as part of test and the in vitro activity of tigecycline”. Journal of Antimicrobial Chemotherapy 60.5 (2007): 1018-1029.
14. Sibghatullah Sheikh., et al. “Risk factors for acquisition of extended spectrum beta lactamase producing Escherichia coli and Klebsi- ella pneumoniae in North-Indian hospitals”. Saudi Journal of Biological Sciences 22.1 (2015): 37-41.
15. Begum Fouzia and Damle AS. “Prevalence and characterization of Extended Spectrum Beta Lactamase production in clinical isolates of K. pneumoniae”. Journal of Medical Microbiology and Diagnosis 4.2 (2015): 1-6.
16. Iraj AlipourFard and Nilufar Yeasmin Nili. “Antibiogram of Extended Spectrum Beta Lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae isolated from Hospital Samples”. Bangladesh Journal of Medical Microbiology 4.1 (2010): 32-36.
17. Reuben Ramphal and Paul G Ambrose. “Extended Spectrum Beta Lactamase and Clinical Outcomes: Current Data”. Clinical Infectious Diseases 42.4 (2006): S164-S172.
18. Majida Q., et al. “Evaluation of extended spectrum beta-lactamase mediated resistance in Escherichia coli and klebsiella in urinary tract infection at a tertiary care hospital”. Biomedia 29 (2013): 78-81.
19. I Iroha., et al. “Susceptibility pattern of extended beta lactamase producing Klebsiella Pneumoniae from Clinical Isolates”. The Internal Journal of Microbiology 5.2 (2007).
20. Daniel Maina., et al. “Antimicrobial resistance patterns in extended spectrum beta lactamase producing Escherichia coli and Klebsi- ella pneumoniae isolates in private tertiary hospital”. Kenya Microbiology Discovery (2013).
21. Abdel Rahman A A., et al. “ESBL –Producing E. coli and K.pneumoniae in Al-Asha, Saudi Arabia: Antibiotic susceptibility and preva- lence of blaSHV and blaTEM”. The Journal of Infection in Developing Countries 7.12 (2013): 1016-1019.
22. Livermore DM. “Beta-lactamase in laboratory and clinical resistance”. Clinical Microbiology Reviews 8.4 (1995): 557-584.
23. Rupp ME and Fey PD. “Extended Spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, pre- vention and drug treatment”. Drugs 63.4 (2003): 353-365.
24. Perez F., et al. “The continuing challenge of ESBLs”. Current Opinion in Pharmacology 7.5 (2007): 459-469.